LON:HCM - Hutchison China MediTech Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 5,270 +220.00 (+4.36 %)
(As of 12/14/2018 04:00 PM ET)
Previous CloseGBX 5,270
Today's RangeGBX 5,090 - GBX 5,310
52-Week RangeGBX 2,840 - GBX 5,932
Volume91,906 shs
Average Volume13,897 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorN/A
Current SymbolLON:HCM
Previous Symbol
CUSIPN/A
Phone+85221213888

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees590
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable

Hutchison China MediTech (LON:HCM) Frequently Asked Questions

What is Hutchison China MediTech's stock symbol?

Hutchison China MediTech trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

What is the consensus analysts' recommendation for Hutchison China MediTech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hutchison China MediTech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hutchison China MediTech.

Has Hutchison China MediTech been receiving favorable news coverage?

Headlines about HCM stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hutchison China MediTech earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.

Who are some of Hutchison China MediTech's key competitors?

Who are Hutchison China MediTech's key executives?

Hutchison China MediTech's management team includes the folowing people:
  • Mr. Chi Keung To BSc, ACGI, MBA, Exec. Chairman (Age 66)
  • Mr. Christian Hogg BSc, MBA, CEO & Exec. Director (Age 52)
  • Mr. Johnny Cheng BEc, CA, CFO & Exec. Director (Age 51)
  • Dr. Weiguo Su Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 61)
  • Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 66)

How do I buy shares of Hutchison China MediTech?

Shares of HCM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hutchison China MediTech's stock price today?

One share of HCM stock can currently be purchased for approximately GBX 5,270.

What is Hutchison China MediTech's official website?

The official website for Hutchison China MediTech is http://www.chi-med.com/.

How can I contact Hutchison China MediTech?

The company can be reached via phone at +85221213888.


MarketBeat Community Rating for Hutchison China MediTech (LON HCM)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech and other stocks. Vote "Outperform" if you believe HCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel